Welcome to our dedicated page for PETVIVO HOLDINGS WTS news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on PETVIVO HOLDINGS WTS stock.
PETVIVO HOLDINGS INC WTS (symbol: PETVW) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. With a strategic approach of leveraging investments in human biomaterials and medical device industries, PETVIVO aims to bring therapeutics to pets in a capital and time-efficient manner. The company's core strategy involves in-licensing proprietary products from human medical device companies for pet use. PETVIVO HOLDINGS INC WTS is the parent company of petvivo, inc, gel-del technologies, inc, and cosmetalife corporation.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will showcase its innovative veterinary medical device, Spryng™, at the 2023 FAEP Ocala Equine Conference on January 21-22, 2023, in Ocala, FL. The company aims to network with equine industry leaders to enhance its OsteoCushion™ Technology, which supports joint health in companion animals, particularly for osteoarthritis treatment. Spryng™ utilizes an injectable formulation of micronized extracellular matrix particles to assist in managing lameness and joint issues. PetVivo's strategy involves leveraging human medical innovations for quicker veterinary solutions.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced a lease for 14,000 sq. ft. in Edina, Minnesota, to expand its production capacity for Spryng™ with OsteoCushion™ Technology and other medical devices. This facility will feature clean rooms for large-scale production, slated to begin in August 2023. CEO John Lai emphasized this expansion aims to meet global demand for Spryng™, a veterinary device addressing lameness in animals. The company holds nineteen patents for its products, reinforcing its commitment to innovative veterinary medical solutions.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced its participation in the Veterinary Meeting & Expo, occurring from January 14-18, 2023, in Orlando, FL. The company will showcase its lead product, Spryng™ with OsteoCushion™ Technology, designed for managing joint afflictions in companion animals. This conference is the largest veterinary event in the U.S., attracting over 10,000 attendees. CEO John Lai expressed enthusiasm for networking with industry leaders to advance the commercialization of veterinary medical devices.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced its application for a dual listing on Upstream, a trading app for digital securities and NFTs. This initiative aims to provide access to a global investor base using USDC digital currency, credit, debit, PayPal, and USD. CEO John Lai emphasized enhancing liquidity and value for shareholders. Approval by MERJ is necessary, but as a Nasdaq issuer, an expedited listing process may be available. PetVivo specializes in biomedical devices for companion animals, with a focus on innovative therapies.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the Sequire Virtual Small Cap Conference on December 8, 2022, at 2:30 PM EST. CEO John Lai will showcase Spryng™ with OsteoCushion™ Technology, a veterinary device designed for managing lameness and joint issues like osteoarthritis in companion animals. This product offers a natural solution with micronized extracellular matrices that reinforce cartilage support and address tissue defects. The event aims to connect small-cap investors with innovative companies in the biomedical space.
PetVivo Holdings reported substantial growth in the second quarter of fiscal 2023. Revenues surged to $223,280, a significant increase from $4,977 year-over-year, primarily driven by sales of their Spryng™ product to MWI Animal Health. Operating expenses rose to $2,194,689 due to costs associated with product launch and public company expenses, leading to an operating loss of $2,119,568. The net loss was $2,111,589, or ($0.21) per share. As of September 30, 2022, the company had $2.3 million in cash and $2.1 million in working capital.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced its participation in the American Association of Equine Practitioners (AAEP) conference from November 19-22, 2022, in San Antonio, Texas. The company will showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed for treating lameness and joint issues like osteoarthritis in animals. CEO John Lai emphasized the importance of networking to advance their veterinary medical device. Additionally, Dr. Joseph Manning will present on the product during the conference, further enhancing the company's visibility within the veterinary community.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) will release its financial results on November 10, 2022, after market close and host a conference call at 4:00 p.m. CT (5:00 p.m. ET) to discuss these results. The live webcast can be accessed through PetVivo's Investor Relations website.
The company focuses on innovative medical therapeutics for animals, with a pipeline of 17 products and 19 patents, including its lead product, SPRYNG™, designed for joint-related afflictions in dogs and horses.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the 15th annual LD Micro Main Event on October 26, 2022, from 08:00 AM to 8:25 AM PT at the Luxe Sunset Boulevard Hotel. CEO John Lai plans to highlight the company's innovative veterinary medical device, SPRYNG, aimed at managing osteoarthritis in animals. The event, running from October 25-27, features over 200 companies. PetVivo has a pipeline of products and holds nineteen patents, ensuring its commitment to developing effective therapies for companion animals.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) announced that its product, Spryng™ with OsteoCushion™ Technology, is now available for purchase through MWI Animal Health. Under an exclusive distribution agreement, MWI will market and promote Spryng to veterinarians across the U.S., expanding its presence in the animal health market. Spryng is designed to treat joint afflictions like osteoarthritis in equine and companion animals. The partnership aims to provide veterinarians with innovative tools for managing lameness, benefiting both animals and their owners.
FAQ
What is the current stock price of PETVIVO HOLDINGS WTS (PETVW)?
What does PETVIVO HOLDINGS INC WTS specialize in?
What is PETVIVO's strategic approach?
How does PETVIVO commercialize products for pets?
What subsidiaries are under PETVIVO HOLDINGS INC?
What is PETVIVO's core business model?
What is the significance of PETVIVO in the biomedical device industry?
How does PETVIVO ensure efficient commercialization of pet therapeutics?
What sets PETVIVO apart in the pet therapeutics market?
What are some recent achievements of PETVIVO HOLDINGS INC WTS?
What can investors expect from PETVIVO's future projects?
